The 2025 International Parkinson and Movement Disorder Congress (MDS 2025) was held in Honolulu, Hawaii, USA, from October 5 to 9, 2025 (local time). The congress is held annually with the aim of advancing diagnosis and treatment and improving the quality of life of patients with movement disorders worldwide.

The theme of this year’s congress was “Toward Disease Modification in Movement Disorders”, focusing on innovative therapies that go beyond traditional symptom management to truly delay or alter disease progression. The congress attracted more than 13,000 experts, scholars, clinicians, and industry representatives from over 130 countries to Honolulu to share the latest breakthroughs in the mechanisms, diagnosis and treatment, neuromodulation, and drug development of Parkinson’s disease and related disorders. The congress featured keynote lectures, thematic sessions, and over 1,800 poster presentations, comprehensively covering basic research, translational advances, artificial intelligence, and clinical frontiers, with the goal of accelerating the global harmonization of diagnosis and treatment for movement disorders and improving patients’ quality of life.

Attending Physician Zhang Meng’s “Multimodal Sensing-Enabled Diagnosis and Assessment of Parkinson’s Disease via Biomolecule and Biomechanics Signals” and Master Xu Jing’s “Efficacy and Safety of Dual-Target Transcranial Magnetic Stimulation in Essential Tremor: A Phase 2 Randomized, Controlled, Patient-Assessor-Blinded Trial”, were presented as posters. These two achievements were from the Parkinson’s and Movement Disorders subspecialty team of the Department of Neurology at the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), led by Professors Qu Qiumin and Cao Hongmei. The on-site exchanges were lively and prompted extensive discussions from attending experts.